Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Merck’s Keytruda shows promise in treating advanced melanoma

Merck & Co. Inc. said long-term data from its cancer immunotherapy Keytruda showed promise in treating advanced melanoma patients, a day after announcing positive lung cancer data from the same treatment.

Read More »

Mixed study results for cancer drug combo

Mixed results were reported from closely watched studies combining Bristol-Myers Squibb’s cancer immunotherapy Opdivo with Nektar Therapeutics’ experimental drug NKTR-214.

Read More »

Keytruda extends lung cancer survival in two trials

Merck & Co.’s immunotherapy Keytruda improved survival as a stand-alone treatment for newly diagnosed lung cancer patients and with chemotherapy for hard-to-treat squamous cell lung cancer.

Read More »

Many women with early-stage breast cancer can skip chemotherapy: study

Some 70 percent of women with early-stage breast cancer and an intermediate risk of cancer recurrence can safely skip chemotherapy after tumor removal, U.S. researchers said.

Read More »

Roche drugs show limited benefit in lung, breast cancer trialsd

In a disappointment for Roche Holding, two of its oncology drugs provided only modest protection from disease progression in lung cancer and breast cancer, according to data from separate clinical trials.

Read More »

Esketamine Shows Promise in Depression Studies

Janssen, part of Johnson & Johnson, announced results from two long-term Phase III trials of esketamine nasal spray in patients with treatment-resistant depression.

Read More »

Madrigal Pharma reports liver drug study success

Madrigal Pharmaceuticals’ shares more than doubled after mid-stage trial data showed the company’s lead drug reduced liver fat in patients with fatty liver disease.

Read More »

AstraZeneca drug Fasenra fails to achieve main goal in COPD trial

AstraZeneca’s first respiratory biological medicine Fasenra failed to meet its main target in a second clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

Read More »

Novo Nordisk’s oral diabetes drug beats Jardiance in study

Novo Nordisk said data from a large final-stage study of a pill the company hopes will transform the diabetes market proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim’s established Jardiance.

Read More »

Genmab, Johnson & Johnson Halt Lung Cancer Study

Genmab and J&J’s Janssen division pulled the plug on the Phase Ib/II trial of daratumumab in combination with Roche’s Tecentriq (atezolizumab) in patients with advanced or metastatic NSCLC.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom